Home > Boards > US Listed > Biotechs > Sage Therapeutics, Inc. (SAGE)

Well it has been - but with the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
cvm101 Member Profile
 
Followed By 0
Posts 267
Boards Moderated 0
Alias Born 04/18/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 9:03:44 AM
Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection Business Wire - 6/14/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/6/2019 4:37:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/6/2019 4:04:04 PM
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - 6/5/2019 6:30:00 AM
Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference Business Wire - 6/4/2019 6:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:04:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 6:26:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 4:02:12 PM
Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Health... PR Newswire (US) - 5/23/2019 9:06:00 AM
Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference Business Wire - 5/14/2019 6:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/10/2019 4:36:46 PM
Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference Business Wire - 5/7/2019 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/6/2019 6:22:29 PM
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - 5/6/2019 4:45:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2019 7:26:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/2/2019 7:17:27 AM
Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire - 5/2/2019 6:30:00 AM
cvm101   Monday, 01/07/19 01:52:11 PM
Re: NYCPuglet post# 76
Post # of 81 
Well it has been - but with the approval to market the new drug its less a speculation and more an investable company. Longer term its worth $200. Most analyst target prices are in that area.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist